Seattle Genetics Company Profile (NASDAQ:SGEN)

About Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics logoSeattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:SGEN
  • CUSIP: 81257810
  • Web:
  • Market Cap: $6.62 billion
  • Outstanding Shares: 143,027,000
Average Prices:
  • 50 Day Moving Avg: $50.86
  • 200 Day Moving Avg: $60.76
  • 52 Week Range: $42.58 - $75.36
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -39.91
  • P/E Growth: -0.06
Sales & Book Value:
  • Annual Revenue: $428.94 million
  • Price / Sales: 15.44
  • Book Value: $4.01 per share
  • Price / Book: 11.55
  • EBIDTA: ($187,250,000.00)
  • Net Margins: -47.38%
  • Return on Equity: -32.87%
  • Return on Assets: -25.17%
  • Current Ratio: 4.47%
  • Quick Ratio: 3.97%
  • Average Volume: 1.18 million shs.
  • Beta: 2.38
  • Short Ratio: 9.81

Frequently Asked Questions for Seattle Genetics (NASDAQ:SGEN)

What is Seattle Genetics' stock symbol?

Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."

How were Seattle Genetics' earnings last quarter?

Seattle Genetics, Inc. (NASDAQ:SGEN) posted its quarterly earnings results on Thursday, July, 27th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.03. The company earned $108.20 million during the quarter, compared to analysts' expectations of $105.92 million. Seattle Genetics had a negative return on equity of 32.87% and a negative net margin of 47.38%. The firm's revenue was up 13.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.23) EPS. View Seattle Genetics' Earnings History.

When will Seattle Genetics make its next earnings announcement?

Seattle Genetics is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Seattle Genetics.

Where is Seattle Genetics' stock going? Where will Seattle Genetics' stock price be in 2017?

19 brokers have issued 12-month target prices for Seattle Genetics' shares. Their forecasts range from $46.00 to $80.00. On average, they expect Seattle Genetics' stock price to reach $61.85 in the next twelve months. View Analyst Ratings for Seattle Genetics.

What are analysts saying about Seattle Genetics stock?

Here are some recent quotes from research analysts about Seattle Genetics stock:

  • 1. Cantor Fitzgerald analysts commented, "The Phase III ECHELON-1 study in previously untreated patients with advanced classical Hodgkin lymphoma met its primary endpoint of modified PFS (82.1% versus 77.2% at two years)." (6/26/2017)
  • 2. Cowen and Company analysts commented, "SGEN announced this morning that following an interim safety look of 33A’s pivotal." (6/19/2017)
  • 3. Cann analysts commented, "Seattle Genetics announced today that it is discontinuing the phase III CASCADE clinical trial of vadastuximab talirine (SGN-CD33A) in frontline older acute myeloid leukemia (AML) patients. Seattle Genetics reported it took this action following consultation with the Independent Data Monitoring Committee (IDMC) and after reviewing unblinded data on June 16, 2017. As a result of the discontinuation of SGN-CD33A (vadastuximab talirine; 33A), we are removing estimated sales of SGN- CD33A from our model in 2020 and 2021." (6/19/2017)
  • 4. J P Morgan Chase & Co analysts commented, "With top-line results for ECHELON-1 (Adcetris in 1L Hodgkin lymphoma) reading out at some point in 2017, we conducted a detailed analysis of the trial design and available data and interviewed a couple more KOLs to help frame expectations. We are also updating our model to better account for doc feedback and re-treatment rates among the various approved Adcetris settings. The bottom line is that we are bullish on the potential success of E-1 (70% in our model), which may offer a favorable trading opportunity into the data." (6/13/2017)
  • 5. According to Zacks Investment Research, "Seattle Genetics missed bottom-line expectations in the first quarter of 2017 but sales came in ahead of estimates. With the recent llabel expansion of Keytruda in the lymphoma indication, investor focus will likely remain on Adcetris sales in the upcoming quarters. A decline in Adcetris sales will hurt the company's top line. Though, the company has a number of candidates in its pipeline, most of them are in early stages of development. Although the clinical hold on several early-stage trials of vadastuximab talirine in acute myeloid leukemia (AML) was lifted in Mar 2017, Seattle Genetics has a long way to go before the candidate comes close to commercialization. However, the company’s collaboration agreement with Takeda for the global development and commercialization of Adcetris is encouraging. Also, collaborations with companies like AbbVie, Bayer, Roche and Pfizer provide it with funds in the form of upfront, milestone and other payments." (5/2/2017)

Who are some of Seattle Genetics' key competitors?

Who are Seattle Genetics' key executives?

Seattle Genetics' management team includes the folowing people:

  • Clay B. Siegall Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Todd E. Simpson, Chief Financial Officer
  • Eric L. Dobmeier, Chief Operating Officer
  • Jean I. Liu J.D., Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
  • Darren S. Cline, Executive Vice President - Commercial
  • Jonathan G. Drachman M.D., Chief Medical Officer, Executive Vice President - Research and Development
  • Vaughn B. Himes Ph.D., Chief Technical Officer
  • Felix J. Baker Ph.D., Lead Independent Director
  • Srinivas Akkaraju M.D. Ph.D., Independent Director
  • David W. Gryska, Independent Director

Who owns Seattle Genetics stock?

Seattle Genetics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (11.07%), FMR LLC (5.50%), Vanguard Group Inc. (5.27%), BlackRock Inc. (5.21%), State Street Corp (1.96%) and Capital International Investors (1.90%). Company insiders that own Seattle Genetics stock include Clay B Siegall, Darren S Cline, David W Gryska, Eric Dobmeier, Felix Baker, John A Orwin, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Institutional Ownership Trends for Seattle Genetics.

Who sold Seattle Genetics stock? Who is selling Seattle Genetics stock?

Seattle Genetics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Artisan Partners Limited Partnership, Wasatch Advisors Inc., Baillie Gifford & Co., Capital Guardian Trust Co., Gotham Asset Management LLC, Wells Fargo & Company MN and KBC Group NV. Company insiders that have sold Seattle Genetics stock in the last year include Clay B Siegall, Darren S Cline, Eric Dobmeier, Jonathan G Drachman, Marc E Lippman and Vaughn B Himes. View Insider Buying and Selling for Seattle Genetics.

Who bought Seattle Genetics stock? Who is buying Seattle Genetics stock?

Seattle Genetics' stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Capital International Investors, Marshall Wace North America L.P., Matrix Capital Management Company LP, TIAA CREF Investment Management LLC, First Trust Advisors LP, Pictet Asset Management Ltd. and Tekla Capital Management LLC. Company insiders that have bought Seattle Genetics stock in the last two years include Felix Baker and John A Orwin. View Insider Buying and Selling for Seattle Genetics.

How do I buy Seattle Genetics stock?

Shares of Seattle Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Seattle Genetics' stock price today?

One share of Seattle Genetics stock can currently be purchased for approximately $46.30.

MarketBeat Community Rating for Seattle Genetics (NASDAQ SGEN)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  285 (Vote Outperform)
Underperform Votes:  325 (Vote Underperform)
Total Votes:  610
MarketBeat's community ratings are surveys of what our community members think about Seattle Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Seattle Genetics (NASDAQ:SGEN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Sell Ratings, 9 Hold Ratings, 7 Buy Ratings
Consensus Rating:Hold (Score: 2.21)
Consensus Price Target: $61.85 (33.58% upside)

Analysts' Ratings History for Seattle Genetics (NASDAQ:SGEN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/16/2017Cantor FitzgeraldSet Price TargetHold$46.00LowView Rating Details
7/28/2017Cowen and CompanyReiterated RatingHold$54.00HighView Rating Details
7/27/2017Jefferies Group LLCReiterated RatingBuy$53.00HighView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
6/27/2017J P Morgan Chase & CoReiterated RatingNeutralHighView Rating Details
6/27/2017Piper Jaffray CompaniesReiterated RatingNeutral$48.00HighView Rating Details
6/23/2017Barclays PLCReiterated RatingHoldMediumView Rating Details
6/21/2017Morgan StanleyLower Price TargetOverweight$70.00 -> $64.00MediumView Rating Details
6/20/2017Needham & Company LLCReiterated RatingBuy$72.00LowView Rating Details
6/19/2017CannReiterated RatingHoldLowView Rating Details
6/15/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldMediumView Rating Details
4/28/2017HC WainwrightBoost Price TargetBuy$65.00 -> $75.00LowView Rating Details
4/7/2017Leerink SwannBoost Price TargetOutperform$70.00 -> $74.00MediumView Rating Details
3/16/2017CIBCInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
2/16/2017Bank of America CorporationDowngradeNeutral -> UnderperformN/AView Rating Details
2/13/2017Credit Suisse GroupBoost Price TargetNeutral$62.00 -> $66.00N/AView Rating Details
1/5/2017Royal Bank Of CanadaSet Price TargetBuy$80.00N/AView Rating Details
1/5/2017Maxim GroupReiterated RatingReduceN/AView Rating Details
9/16/2016Goldman Sachs Group, Inc. (The)DowngradeNeutral -> SellN/AView Rating Details
7/27/2016SunTrust Banks, Inc.Boost Price TargetNeutral$34.00 -> $38.00N/AView Rating Details
(Data available from 8/20/2015 forward)


Earnings History for Seattle Genetics (NASDAQ:SGEN)
Earnings by Quarter for Seattle Genetics (NASDAQ:SGEN)
Earnings History by Quarter for Seattle Genetics (NASDAQ SGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017($0.40)N/AView Earnings Details
7/27/2017Q2 2017($0.42)($0.39)$105.92 million$108.20 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.41)($0.42)$103.23 million$109.10 millionViewN/AView Earnings Details
2/9/2017Q416($0.34)($0.39)$106.49 million$105.30 millionViewListenView Earnings Details
10/27/2016Q316($0.29)($0.23)$4.34 million$106.30 millionViewListenView Earnings Details
7/26/2016Q216($0.32)($0.23)$94.56 million$95.40 millionViewListenView Earnings Details
4/28/2016Q116($0.09)($0.15)$116.49 million$111.15 millionViewListenView Earnings Details
2/9/2016Q415($0.20)($0.18)$88.00 million$93.50 millionViewN/AView Earnings Details
10/29/2015Q315($0.20)($0.21)$82.35 million$84.10 millionViewListenView Earnings Details
7/30/2015Q215($0.26)($0.38)$78.21 million$77.10 millionViewListenView Earnings Details
4/30/2015Q1($0.19)($0.17)$74.57 million$82.20 millionViewListenView Earnings Details
2/10/2015Q414($0.25)($0.22)$68.34 million$74.30 millionViewListenView Earnings Details
10/30/2014Q314($0.24)($0.13)$66.90 million$75.80 millionViewListenView Earnings Details
7/31/2014Q214($0.23)($0.14)$65.04 million$68.30 millionViewListenView Earnings Details
5/1/2014Q114($0.21)($0.13)$64.62 million$68.30 millionViewListenView Earnings Details
2/11/2014Q413($0.24)($0.13)$59.50 million$67.40 millionViewListenView Earnings Details
11/5/2013Q313($0.22)($0.19)$57.79 million$71.00 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.20)($0.06)$58.12 million$773.60 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.19)($0.14)$53.72 million$57.32 millionViewListenView Earnings Details
2/12/2013Q4 2012($0.10)($0.09)$57.21 million$63.90 millionViewListenView Earnings Details
11/7/2012Q312($0.14)($0.12)$52.79 million$49.83 millionViewN/AView Earnings Details
8/8/2012($0.15)($0.15)ViewN/AView Earnings Details
5/8/2012($0.11)($0.11)ViewN/AView Earnings Details
2/13/2012($0.31)($0.24)ViewN/AView Earnings Details
11/3/2011($0.46)($0.35)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Seattle Genetics (NASDAQ:SGEN)
2017 EPS Consensus Estimate: ($1.47)
2018 EPS Consensus Estimate: ($1.38)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.39)($0.39)($0.39)
Q2 20173($0.44)($0.28)($0.37)
Q3 20174($0.47)($0.19)($0.34)
Q4 20174($0.50)($0.23)($0.37)
Q1 20181($0.42)($0.42)($0.42)
Q2 20181($0.33)($0.33)($0.33)
Q3 20181($0.25)($0.25)($0.25)
Q4 20181($0.38)($0.38)($0.38)
(Data provided by Zacks Investment Research)


Dividend History for Seattle Genetics (NASDAQ:SGEN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Seattle Genetics (NASDAQ:SGEN)
Insider Ownership Percentage: 33.30%
Institutional Ownership Percentage: 98.21%
Insider Trades by Quarter for Seattle Genetics (NASDAQ:SGEN)
Institutional Ownership by Quarter for Seattle Genetics (NASDAQ:SGEN)
Insider Trades by Quarter for Seattle Genetics (NASDAQ:SGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/7/2017Clay B. SiegallInsiderSell10,413$48.91$509,299.83View SEC Filing  
8/7/2017Darren S. ClineEVPSell6,000$49.19$295,140.00View SEC Filing  
7/27/2017Jonathan G. DrachmanCMOSell10,000$54.54$545,400.00View SEC Filing  
7/5/2017Clay B. SiegallCEOSell10,423$51.98$541,787.54View SEC Filing  
6/22/2017Jonathan G DrachmanCMOSell10,000$64.01$640,100.00View SEC Filing  
6/5/2017Clay B. SiegallInsiderSell10,423$65.21$679,683.83View SEC Filing  
4/5/2017Clay B SiegallInsiderSell14,465$62.99$911,150.35View SEC Filing  
3/31/2017Vaughn B HimesInsiderSell10,000$62.75$627,500.00View SEC Filing  
3/6/2017Clay B SiegallCEOSell14,465$68.04$984,198.60View SEC Filing  
2/6/2017Clay B SiegallInsiderSell14,465$61.54$890,176.10View SEC Filing  
1/6/2017Clay B. SiegallInsiderSell14,465$57.89$837,378.85View SEC Filing  
12/13/2016Darren S. ClineEVPSell10,000$63.38$633,800.00View SEC Filing  
12/8/2016Eric DobmeierCOOSell12,500$65.92$824,000.00View SEC Filing  
12/7/2016Vaughn B. HimesInsiderSell30,000$65.32$1,959,600.00View SEC Filing  
11/8/2016Felix BakerDirectorBuy382,500$59.36$22,705,200.00View SEC Filing  
11/7/2016Clay B. SiegallCEOSell14,465$58.43$845,189.95View SEC Filing  
11/7/2016Marc E. LippmanDirectorSell1,000$57.75$57,750.00View SEC Filing  
11/3/2016Felix BakerDirectorBuy1,030,629$56.13$57,849,205.77View SEC Filing  
11/1/2016Jonathan G. DrachmanCMOSell3,418$51.74$176,847.32View SEC Filing  
10/6/2016Clay B. SiegallInsiderSell14,465$54.41$787,040.65View SEC Filing  
9/22/2016Jonathan G DrachmanCMOSell2,249$56.75$127,630.75View SEC Filing  
9/14/2016Eric DobmeierCOOSell22,918$54.04$1,238,488.72View SEC Filing  
9/13/2016Felix BakerDirectorBuy447,311$50.71$22,683,140.81View SEC Filing  
9/8/2016Clay B. SiegallInsiderSell31,269$50.08$1,565,951.52View SEC Filing  
9/8/2016Felix BakerDirectorBuy414,016$48.43$20,050,794.88View SEC Filing  
8/23/2016Eric DobmeierCOOSell12,589$48.00$604,272.00View SEC Filing  
8/22/2016Clay B. SiegallInsiderSell23,381$46.59$1,089,320.79View SEC Filing  
8/22/2016Eric DobmeierCOOSell5,411$46.59$252,098.49View SEC Filing  
8/22/2016Vaughn B. HimesEVPSell3,991$46.59$185,940.69View SEC Filing  
8/8/2016Clay B. SiegallInsiderSell11,660$47.19$550,235.40View SEC Filing  
7/27/2016Clay B. SiegallInsiderSell4,042$45.20$182,698.40View SEC Filing  
7/6/2016Clay B. SiegallCEOSell7,618$40.56$308,986.08View SEC Filing  
6/6/2016Clay B SiegallCEOSell22,083$43.59$962,597.97View SEC Filing  
6/2/2016Darren S ClineEVPSell3,366$42.07$141,607.62View SEC Filing  
5/27/2016Clay B SiegallCEOSell48,660$40.41$1,966,350.60View SEC Filing  
5/24/2016Clay B SiegallCEOSell8,400$40.09$336,756.00View SEC Filing  
5/23/2016Clay B SiegallCEOSell6,700$40.12$268,804.00View SEC Filing  
5/17/2016Clay B SiegallCEOSell7,618$35.16$267,848.88View SEC Filing  
4/25/2016Clay B SiegallCEOSell800$40.00$32,000.00View SEC Filing  
4/5/2016Clay B SiegallCEOSell7,618$36.12$275,162.16View SEC Filing  
3/22/2016Clay B SiegallCEOSell15,236$35.52$541,182.72View SEC Filing  
3/21/2016Clay B SiegallCEOSell4,282$35.01$149,912.82View SEC Filing  
3/17/2016Felix BakerDirectorBuy124,065$31.85$3,951,470.25View SEC Filing  
3/16/2016Felix BakerDirectorBuy1,349,237$32.10$43,310,507.70View SEC Filing  
3/15/2016Felix BakerDirectorBuy661,093$32.08$21,207,863.44View SEC Filing  
3/14/2016Felix BakerDirectorBuy118,941$33.77$4,016,637.57View SEC Filing  
3/11/2016Felix BakerDirectorBuy694,666$32.46$22,548,858.36View SEC Filing  
3/8/2016Felix BakerDirectorBuy502,523$22.66$11,387,171.18View SEC Filing  
3/2/2016Felix BakerDirectorBuy675,922$31.77$21,474,041.94View SEC Filing  
3/1/2016Felix BakerDirectorBuy24,200$31.24$756,008.00View SEC Filing  
2/29/2016Felix BakerDirectorBuy251,722$30.39$7,649,831.58View SEC Filing  
2/26/2016Felix BakerDirectorBuy314,508$29.55$9,293,711.40View SEC Filing  
2/22/2016Felix BakerDirectorBuy1,001,471$29.63$29,673,585.73View SEC Filing  
2/17/2016Felix BakerDirectorBuy1,269,147$30.43$38,620,143.21View SEC Filing  
2/12/2016John A. OrwinDirectorBuy2,000$28.33$56,660.00View SEC Filing  
12/15/2015Vaughn B. HimesEVPSell40,500$39.94$1,617,570.00View SEC Filing  
12/3/2015Clay B. SiegallCEOSell3,720$39.99$148,762.80View SEC Filing  
11/20/2015Felix BakerDirectorBuy329,358$43.94$14,471,990.52View SEC Filing  
11/17/2015Clay B SiegallCEOSell87,473$45.40$3,971,274.20View SEC Filing  
11/11/2015Darren S ClineSVPSell5,769$45.68$263,527.92View SEC Filing  
11/10/2015Felix BakerDirectorBuy934,624$42.95$40,142,100.80View SEC Filing  
11/9/2015Felix BakerDirectorBuy507,300$43.76$22,199,448.00View SEC Filing  
11/6/2015Eric DobmeierCOOSell17,452$42.50$741,710.00View SEC Filing  
11/6/2015Felix BakerDirectorBuy417,924$41.94$17,527,732.56View SEC Filing  
11/5/2015David W GryskaDirectorSell10,000$43.57$435,700.00View SEC Filing  
11/4/2015Clay B. SiegallCEOSell3,718$43.14$160,394.52View SEC Filing  
10/5/2015Clay B. SiegallCEOSell3,718$41.30$153,553.40View SEC Filing  
9/3/2015Clay B. SiegallCEOSell3,718$40.12$149,166.16View SEC Filing  
8/20/2015Clay B. SiegallCEOSell31,754$42.02$1,334,303.08View SEC Filing  
8/20/2015Darren S. ClineSVPSell2,231$42.02$93,746.62View SEC Filing  
8/20/2015Eric DobmeierCOOSell8,548$42.02$359,186.96View SEC Filing  
8/20/2015Jonathan G. DrachmanCMOSell4,462$42.02$187,493.24View SEC Filing  
8/20/2015Todd E. SimpsonCFOSell5,825$42.02$244,766.50View SEC Filing  
8/20/2015Vaughn B. HimesEVPSell5,997$42.02$251,993.94View SEC Filing  
7/6/2015Clay B SiegallCEOSell3,718$46.94$174,522.92View SEC Filing  
6/3/2015Clay B SiegallCEOSell3,718$45.72$169,986.96View SEC Filing  
5/21/2015Felix BakerDirectorBuy950,886$42.49$40,403,146.14View SEC Filing  
5/8/2015Eric DobmeierCOOSell17,074$40.38$689,448.12View SEC Filing  
5/7/2015Felix BakerDirectorBuy1,032,664$35.56$36,721,531.84View SEC Filing  
3/10/2015Felix BakerDirectorBuy285,036$34.66$9,879,347.76View SEC Filing  
3/9/2015Felix BakerDirectorBuy275,717$34.66$9,556,351.22View SEC Filing  
3/4/2015Felix BakerDirectorBuy448,841$34.84$15,637,620.44View SEC Filing  
2/25/2015Felix BakerDirectorBuy281,115$33.92$9,535,420.80View SEC Filing  
1/6/2015Clay B SiegallCEOSell16,804$31.80$534,367.20View SEC Filing  
12/16/2014Felix BakerDirectorBuy2,883,378$31.86$91,864,423.08View SEC Filing  
12/10/2014Felix BakerDirectorBuy1,247,896$33.82$42,203,842.72View SEC Filing  
12/9/2014Felix BakerDirectorBuy128,430$34.16$4,387,168.80View SEC Filing  
12/8/2014Felix BakerDirectorBuy465,316$32.93$15,322,855.88View SEC Filing  
11/12/2014Vaughn B HimesEVPSell10,000$37.52$375,200.00View SEC Filing  
11/10/2014Felix BakerDirectorBuy1,653,925$34.56$57,159,648.00View SEC Filing  
9/4/2014Clay B SiegallCEOSell5,600$42.54$238,224.00View SEC Filing  
8/12/2014Clay B SiegallCEOSell11,200$40.38$452,256.00View SEC Filing  
8/11/2014Clay B SiegallCEOSell2,700$40.05$108,135.00View SEC Filing  
6/13/2014Felix BakerDirectorBuy216,595$39.92$8,646,472.40View SEC Filing  
6/10/2014Clay B SiegallCEOSell11,200$40.14$449,568.00View SEC Filing  
6/9/2014Felix BakerDirectorBuy546,252$38.16$20,844,976.32View SEC Filing  
6/4/2014Felix BakerDirectorBuy281,963$34.86$9,829,230.18View SEC Filing  
5/16/2014Felix BakerDirectorBuy189,611$34.07$6,460,046.77View SEC Filing  
4/3/2014Clay SiegallCEOSell5,600$43.34$242,704.00View SEC Filing  
2/18/2014Clay SiegallCEOSell100,000$51.97$5,197,000.00View SEC Filing  
1/21/2014Eric DobmeierCOOSell56,010$47.92$2,683,999.20View SEC Filing  
1/16/2014Jonathan DrachmanCMOSell1,201$45.75$54,945.75View SEC Filing  
12/16/2013Felix BakerDirectorBuy407,078$39.66$16,144,713.48View SEC Filing  
12/5/2013Felix BakerDirectorBuy1,005,901$43.19$43,444,864.19View SEC Filing  
10/1/2013Clay B SiegallCEOSell2,000$43.87$87,740.00View SEC Filing  
9/10/2013Eric DobmeierCOOSell42,000$46.40$1,948,800.00View SEC Filing  
9/5/2013Eric DobmeierCOOSell75,000$42.64$3,198,000.00View SEC Filing  
9/3/2013Clay B SiegallCEOSell102,000$43.90$4,477,800.00View SEC Filing  
9/3/2013David W GryskaDirectorSell10,000$42.48$424,800.00View SEC Filing  
8/27/2013Todd SimpsonCFOSell37,763$41.45$1,565,276.35View SEC Filing  
8/19/2013Clay SiegallCEOSell7,653$40.91$313,084.23View SEC Filing  
8/19/2013Eric DobmeierCOOSell3,328$40.91$136,148.48View SEC Filing  
8/19/2013Vaughn HimesEVPSell1,736$40.91$71,019.76View SEC Filing  
8/1/2013Clay B SiegallCEOSell2,000$40.03$80,060.00View SEC Filing  
7/12/2013Todd E SimpsonCFOSell92,527$37.45$3,465,136.15View SEC Filing  
7/1/2013Clay B SiegallCEOSell2,000$32.59$65,180.00View SEC Filing  
6/14/2013Srinivas AkkarajuDirectorSell5,000$32.75$163,750.00View SEC Filing  
6/13/2013Vaughn B HimesEVPSell10,000$32.11$321,100.00View SEC Filing  
6/3/2013Clay B SiegallCEOSell2,000$33.88$67,760.00View SEC Filing  
5/10/2013Srinivas AkkarajuDirectorSell17,500$37.17$650,475.00View SEC Filing  
3/6/2013Eric DobmeierCOOSell100,000$29.68$2,968,000.00View SEC Filing  
2/25/2013David W GryskaDirectorSell10,000$27.17$271,700.00View SEC Filing  
2/1/2013Clay B SiegallCEOSell2,000$29.61$59,220.00View SEC Filing  
1/15/2013Thomas C ReynoldsInsiderSell125,079$28.00$3,502,212.00View SEC Filing  
11/1/2012Clay B SiegallCEOSell8,250$25.51$210,457.50View SEC Filing  
9/4/2012Clay B SiegallCEOSell8,250$26.54$218,955.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Seattle Genetics (NASDAQ:SGEN)
Latest Headlines for Seattle Genetics (NASDAQ:SGEN)
DateHeadline logoQ3 2018 Earnings Forecast for Seattle Genetics, Inc. Issued By Oppenheimer Holdings (SGEN) - August 18 at 11:40 AM logoSeattle Genetics (SGEN) Says FDA Accepts sBLA and Grants Priority Review for ADCETRIS in Cutaneous T-Cell ... - - August 17 at 9:39 PM logoSeattle Genetics' Adcetris Granted Priority Review by FDA - Nasdaq - August 17 at 9:39 PM logoSeattle Genetics, Inc. Forecasted to Post Q1 2018 Earnings of ($0.42) Per Share (SGEN) - August 17 at 12:02 PM logoSeattle Genetics (SGEN) Says FDA Accepts sBLA and Grants Priority Review for ADCETRIS in Cutaneous T-Cell Lymphoma - August 17 at 7:31 AM logoFDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma - August 17 at 7:31 AM logoSeattle Genetics, Inc. (SGEN) Given a $46.00 Price Target by Cantor Fitzgerald Analysts - August 16 at 8:58 PM logoFDA accepts Seattle Genetics marketing application for Adcetris for CTCL, action date December 16; shares ahead 1% - August 16 at 10:46 AM logoIHS Markit Score upgrades Seattle Genetics Inc to 75 out of 100, despite ranking positively in only one IHS Markit category. - August 11 at 8:25 AM logoCantor Fitzgerald Comments on Seattle Genetics, Inc.'s FY2017 Earnings (NASDAQ:SGEN) - August 10 at 10:42 AM logoSee what the IHS Markit Score report has to say about Seattle Genetics Inc. - August 10 at 7:49 AM logoSeattle Genetics, Inc. (NASDAQ:SGEN) EVP Sells $295,140.00 in Stock - August 9 at 8:44 PM logoSeattle Genetics, Inc. (NASDAQ:SGEN) Insider Clay B. Siegall Sells 10,413 Shares - August 9 at 8:22 PM logoSeattle Genetics, Inc. (NASDAQ:SGEN) Receives Average Recommendation of "Hold" from Brokerages - August 8 at 7:47 AM logoCorporate News Blog - Paul Sekhri Appointed Chairman of Board at Drug Discovery Company Compugen - August 4 at 8:05 AM logoSeattle Genetics, Inc. (NASDAQ:SGEN) Stock Rating Lowered by BidaskClub - August 3 at 12:06 AM logoSeattle Genetics buys Bristol-Myers Squibb drug manufacturing facility in Bothell - August 2 at 1:50 AM logoSeattle Genetics Announces Purchase of Bothell Manufacturing Facility from Bristol-Myers Squibb - Business Wire (press release) - August 1 at 8:49 PM logoSeattle Genetics Announces Purchase of Bothell Manufacturing Facility from Bristol-Myers Squibb - August 1 at 8:49 PM logoJonathan G. Drachman Sells 10,000 Shares of Seattle Genetics, Inc. (SGEN) Stock - July 31 at 10:28 PM logoSeattle Genetics, Inc.: Expanded Sales on Their Way (FDA Willing) - July 31 at 4:28 PM logoEdited Transcript of SGEN earnings conference call or presentation 27-Jul-17 8:30pm GMT - July 30 at 6:10 AM logoSeattle Genetics (SGEN) Q2 Loss Narrower than Expected - Nasdaq - July 29 at 7:11 AM logoSeattle Genetics (SGEN) Q2 Loss Narrower than Expected - July 29 at 7:11 AM logoEARNINGS SUMMARY: Details of Seattle Genetics Inc. Q2 Earnings Report - July 28 at 7:50 AM logoBRIEF-Seattle Genetics Q2 loss per share $0.39 - July 28 at 7:50 AM logoSeattle Genetics (SGEN) Q2 2017 Results - Earnings Call Transcript - July 28 at 7:50 AM logoSeattle Genetics Reports Second Quarter 2017 Financial Results - July 28 at 7:50 AM logoSeattle Genetics reports 2Q loss - July 28 at 7:50 AM logoSeattle Genetics, Inc. (SGEN) Announces Quarterly Earnings Results - July 27 at 9:21 PM logoSeattle Genetics, Inc. (SGEN) Given "Buy" Rating at Jefferies Group LLC - July 27 at 5:54 PM logoSeattle Genetics Gets Canadian Marketing Authorization For Adcetris - July 27 at 7:22 AM logoSeattle Genetics (SGEN) Granted Approval of ADCETRIS (Brentuximab Vedotin) - July 27 at 7:22 AM logoSeattle Genetics (SGEN) Reports Clinical Collaboration to Expand Therapeutic Evaluation of SGN-LIV1A - - July 26 at 7:13 AM logoSeattle Genetics (SGEN) Granted Approval of ADCETRIS (Brentuximab Vedotin) - - July 26 at 7:13 AM logoHealth Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Post-ASCT Consolidation Treatment of Patients with Hodgkin Lymphoma at Increased Risk of Relapse or Progression - July 26 at 7:13 AM logoBRIEF-Seattle Genetics announces clinical collaboration to expand the therapeutic evaluation of sgn-liv1a - July 25 at 6:37 AM logoSeattle Genetics Announces Clinical Collaboration to Expand the Therapeutic Evaluation of SGN-LIV1A in Triple Negative Breast Cancer - July 25 at 6:37 AM logo$107.20 Million in Sales Expected for Seattle Genetics, Inc. (SGEN) This Quarter - July 19 at 4:54 PM logo Analysts Expect Seattle Genetics, Inc. (SGEN) to Announce -$0.43 EPS - July 17 at 10:54 AM logoResearch Analysts Set Expectations for Seattle Genetics, Inc.'s Q3 2017 Earnings (SGEN) - July 17 at 8:11 AM logoSeattle Genetics, Inc. (NASDAQ:SGEN) Given Consensus Rating of "Hold" by Brokerages - July 14 at 9:06 AM logoInsider Selling: Seattle Genetics, Inc. (NASDAQ:SGEN) CEO Sells 10,423 Shares of Stock - July 7 at 8:16 PM logoSeattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter Financial Results on July 27, 2017 - July 6 at 8:55 AM logoFY2018 EPS Estimates for Seattle Genetics, Inc. Lowered by Analyst (SGEN) - June 29 at 11:36 AM logoBidaskClub Lowers Seattle Genetics, Inc. (SGEN) to Sell - June 28 at 4:56 PM logoFBT's Underlying Holdings Could Mean 11% Gain Potential - Nasdaq - June 28 at 3:23 PM logoSeattle Genetics (SGEN) Reports Positive Data for Adcetris - Nasdaq - June 28 at 8:18 AM logoSeattle Genetics' (SGEN) Outperform Rating Reiterated at William Blair - June 28 at 7:32 AM logoAnalysts Issue Forecasts for Seattle Genetics, Inc.'s Q2 2017 Earnings (SGEN) - June 28 at 7:24 AM



Seattle Genetics (SGEN) Chart for Sunday, August, 20, 2017

This page was last updated on 8/20/2017 by Staff